GlassScriptPhysician profile
John M Bosworth
NPI 1750339743
$4,387.63
in general payments reported to CMS, 2019-2025
20 companies · $995 in 2025
The $995 reported for 2025 was more than what 79% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $66.32 · 2021: $426 · 2022: $156 · 2023: $743 · 2024: $1,305 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035 · Consulting Fee: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,034.94 |
| Consulting Fee | $1,007.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $929.59 | 2023-2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Aerin Medical INC. | $877.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $477.54 | 2021-2025 | Nucala |
| Acclarent, INC | $383.54 | 2019-2022 | |
| Genzyme Corporation | $371.67 | 2019-2025 | |
| Optinose US, INC. | $368.65 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $294.12 | 2019-2025 | Dupixent |
| Intersect Ent, INC. | $219.81 | 2019-2022 | |
| Inspire Medical Systems, INC. | $132.74 | 2024-2025 | Inspire |
| Hikma Pharmaceuticals USA | $62.51 | 2023-2024 | Ryaltris |
| Phathom Pharmaceuticals, INC. | $44.73 | 2025 | Voquezna |
| Smith+Nephew, INC. | $42.73 | 2019 | |
| Merck Sharp & Dohme LLC | $39.40 | 2023 | |
| Amgen INC. | $36.41 | 2025 | Tezspire |
| Stryker Corporation | $29.07 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $25.47 | 2024-2025 | Watchpatone |
| Fortovia Therapeutics, INC. | $15.35 | 2019 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Alk-Abello, INC | $12.09 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bosworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.